TAKEDA PHARMACEUTICAL CO LTD
Known title: 10% OwnerCIK: 0001395064
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Takeda Launches Narcolepsy Drug in Asia, Presents PID Study Data. Takeda has launched its new narcolepsy treatment, ORZEYFUL, in Japan and China, marking the first availability of this orexin agonist for patients with narcolepsy type 1. The company also presented Phase 2/3 clinical data for its investigational drug TAK-881 for primary immunodeficiency disease at a recent medical conference. These pipeline advancements represent key milestones in Takeda's therapeutic portfolio expansion.
this person other insiders at TAK
Transaction History
| OVID | ▼ Sell | Other | 1,250,000 | $0 | 12/8/2025 | View on chart |
| TAK | ▼ Sell | Other | 6,724,000 | $13.1M | 9/17/2025 | View on chart |
| TAK | ▼ Sell | Open Market | 3,703,703 | $30.0M | 1/24/2024 | View on chart |
| TAK | ▼ Sell | Other | 5,883,500 | $0 | 11/30/2022 | View on chart |
| OVID | ▼ Sell | Other | 5,750,000 | $0 | 7/1/2022 | View on chart |
| OVID | ▼ Sell | Other | 5,750,000 | $0 | 7/1/2022 | View on chart |
| TAK | ▼ Sell | Other | 7,359,304 | $0 | 3/14/2022 | View on chart |
| TAK | ▼ Sell | Open Market | 18 | $342 | 3/14/2022 | View on chart |
| TAK | ▼ Sell | Open Market | 110,338 | $2.0M | 12/8/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 58,190 | $1.1M | 12/7/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 128,745 | $2.4M | 12/7/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 97,692 | $1.8M | 12/6/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 12,517 | $231K | 12/3/2021 | View on chart |
| TAK | ▼ Sell | Other | 57,224 | $0 | 11/24/2021 | View on chart |
| TAK | ▼ Sell | Other | 228,696 | $0 | 11/4/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 1 | $19 | 11/4/2021 | View on chart |
| TAK | ▼ Sell | Open Market | 1,000,000 | $20.9M | 11/4/2021 | View on chart |
| TAK | ▼ Sell | Other | 1,475,121 | — | 10/26/2021 | View on chart |
| TAK | ▼ Sell | Other | 1,615,427 | — | 10/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Ovid Therapeutics shares decline in pre-market session
Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.
Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.